One of the most common questions from 503A pharmacy operators is whether they can source finished preparations from 503B outsourcing facilities rather than compounding everything in-house. The short answer is yes — but the regulatory framework governing this relationship is specific, and getting it wrong creates compliance risk for both parties.

This post explains exactly how the 503A-to-503B supply relationship works, what the legal requirements are, and what 503A pharmacies need to do to use this pathway correctly.

503A pharmacies compound patient-specific preparations based on individual prescriptions. They are not required to compound every preparation themselves — they can source certain products from other licensed entities, including 503B outsourcing facilities.

Reasons a 503A pharmacy might source from a 503B facility include:

• Capacity: The 503A pharmacy lacks the equipment, cleanroom space, or staff to compound certain sterile preparations in-house
• Quality: 503B facilities operate under FDA cGMP standards, which may provide higher quality assurance than the 503A pharmacy can achieve internally
• Efficiency: For high-volume preparations, sourcing from a 503B facility may be more efficient than compounding in-house
• BUD: 503B preparations may have longer BUDs than the 503A pharmacy can achieve with its own compounding capabilities
• Compliance: Using a 503B-sourced preparation may reduce the 503A pharmacy's compliance burden for certain high-risk preparations

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Section 503B governs outsourcing facilities. These are distinct regulatory categories with different requirements and different permitted activities.

A 503A pharmacy can purchase preparations from a 503B outsourcing facility. This is explicitly contemplated in the regulatory framework. The 503B facility sells its preparations to licensed healthcare practitioners and pharmacies; the 503A pharmacy is a licensed pharmacy and can be a customer.

However, there are important restrictions:

The 503A pharmacy cannot re-label the 503B preparation as its own compounded product. The preparation must be dispensed with the 503B facility's labeling (or with labeling that accurately reflects the 503B source). Representing a 503B-manufactured preparation as the 503A pharmacy's own compounded product would be misleading and potentially fraudulent.

The 503A pharmacy must have a valid prescription for the patient before dispensing the 503B preparation to that patient. The 503B facility can sell to the 503A pharmacy without a patient-specific prescription, but the 503A pharmacy cannot dispense to a patient without one.

The 503A pharmacy remains responsible for the preparation it dispenses. Sourcing from a 503B facility does not transfer liability to the 503B facility for the 503A pharmacy's dispensing decisions.

In addition to federal law, 503A pharmacies must comply with their state board of pharmacy regulations. State requirements vary, and some states have specific rules about:

• Whether a 503A pharmacy can source preparations from out-of-state 503B facilities
• Labeling requirements for preparations sourced from 503B facilities
• Documentation and record-keeping requirements for sourced preparations
• Whether the 503A pharmacy must inspect or test sourced preparations before dispensing

503A pharmacies should consult with their state board of pharmacy or a regulatory attorney before establishing a 503B sourcing relationship to ensure compliance with state-specific requirements.

When sourcing from a 503B facility, a 503A pharmacy should maintain:

• Purchase records: Documentation of each order placed with the 503B facility, including the product, lot number, quantity, and date
• Certificates of Analysis (CoAs): The 503B facility's CoA for each lot, confirming potency, sterility, and other quality attributes
• BUD records: Documentation of the BUD assigned by the 503B facility and confirmation that preparations are dispensed within that BUD
• Storage records: Temperature logs confirming the preparations were stored as labeled from receipt through dispensing
• Prescription records: Patient-specific prescriptions for each patient who receives a sourced preparation
• Dispensing records: Documentation of which lot was dispensed to which patient

This documentation is essential for compliance and for responding to any adverse event or regulatory inquiry.

Not all 503B outsourcing facilities are equal. When evaluating a 503B supplier, a 503A pharmacy should consider:

FDA registration and inspection history: Confirm the facility is registered with the FDA as a 503B outsourcing facility. Review the FDA's inspection database for any warning letters, Form 483 observations, or other enforcement actions.

Quality systems: Ask about the facility's quality management system, including its procedures for sterility testing, potency testing, environmental monitoring, and deviation management.

Stability data: Ask for the stability data supporting the BUDs assigned to the preparations you intend to source. A reputable 503B facility will have this data and will share it.

CoA availability: Confirm the facility provides a CoA for each lot and that the CoA includes all relevant quality attributes.

Regulatory compliance: Ask about the facility's compliance with USP <797> (2023 revision) and cGMP requirements.

MedClinic Partners works with licensed 503A pharmacies to connect them with vetted 503B supply pathways. Our network includes 503B outsourcing facilities that operate under FDA cGMP oversight and can provide the quality documentation that 503A pharmacies need to source with confidence.

We help 503A pharmacies:

• Identify appropriate 503B supply partners for their specific product needs
• Understand the regulatory requirements for sourcing from 503B facilities
• Navigate state-specific requirements in their jurisdiction
• Access USA-made cGMP RUO peptides on the same platform as compounding supply

If your 503A pharmacy is looking to expand its supply options or improve the quality of the preparations it dispenses, the 503B sourcing pathway is worth exploring.

1. Federal Food, Drug, and Cosmetic Act, Section 503A (21 U.S.C. § 353a) — Pharmacy Compounding.
2. Federal Food, Drug, and Cosmetic Act, Section 503B (21 U.S.C. § 353b) — Outsourcing Facilities.
3. U.S. Food and Drug Administration. Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA, updated 2024.
4. U.S. Food and Drug Administration. Registered Outsourcing Facilities. FDA database, accessed 2026.
5. National Association of Boards of Pharmacy. Model State Pharmacy Act and Model Rules. NABP, 2023.

MedClinic Partners connects licensed 503A pharmacies with vetted 503B supply pathways and USA-made cGMP RUO peptides. Questions about 503B sourcing? Use the Get Connected form to reach our team.